UPDATED: FDA experts spurn AstraZeneca’s pitch for ovarian cancer drug olaparib

John Carroll

AstraZeneca's top investigators took their best case for an accelerated approval of the failed to the FDA's panel of outside on Wednesday, and they lost.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS